Neuberger Berman Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.92M Buy
83,223
+188
+0.2% +$20.1K 0.01% 930
2026
Q2
$9.22M Buy
83,035
+9,601
+13% +$868K 0.01% 901
2026
Q1
$6.39M Sell
73,434
-138
-0.2% -$13.4K ﹤0.01% 934
2025
Q4
$7.88M Sell
73,572
-11,545
-14% -$1.22M 0.01% 863
2025
Q3
$8.6M Sell
85,117
-1,022
-1% -$94.9K 0.01% 839
2025
Q2
$5.44M Buy
86,139
+18,200
+27% +$1.11M ﹤0.01% 945
2025
Q1
$3.6M Buy
+67,939
New +$3.77M ﹤0.01% 999

Other funds holding RYTM

Neuberger Berman Group's RYTM Position: Q3 2026 in Review

Neuberger Berman Group increased its Rhythm Pharmaceuticals (RYTM) stake by 0.23% in Q3 2026, buying an estimated $20.1K and bringing the position to 83,223 shares worth $7.92M. The position accounts for 0.01% of the portfolio, ranked #930.

Neuberger Berman Group first reported a position in RYTM in Q1 2025 and has held it in 7 quarters since. The position peaked at $9.22M in Q2 2026. 332 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

  • Neuberger Berman Group held 83,223 shares of Rhythm Pharmaceuticals worth $7.92M as of Q3 2026.
  • Neuberger Berman Group bought 188 Rhythm Pharmaceuticals shares in Q3 2026, an estimated $20.1K.
  • Rhythm Pharmaceuticals made up 0.01% of Neuberger Berman Group's portfolio in Q3 2026, its #930 holding.
  • Neuberger Berman Group first reported a position in Rhythm Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
  • Neuberger Berman Group's Rhythm Pharmaceuticals position peaked at $9.22M in Q2 2026.
  • 332 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on Neuberger Berman Group's 13F filing for Q3 2026, filed 13 Nov 2026.